DESCRIBE <http://purl.uniprot.org/citations/19603021>

Subject	Predicate	Object
http://purl.uniprot.org/citations/19603021	http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/19603021	http://www.w3.org/2000/01/rdf-schema#comment	" Background Epithelial ovarian cancer is one of the most lethal malignancies, and has a high recurrence rate. Thus, prognostic markers for recurrence are crucial for the care of ovarian cancer. As ovarian cancers frequently exhibit chromosome instability, we aimed at assessing the prognostic significance of two key mitotic kinases, BubR1 and Aurora A. Methods We analysed paraffin-embedded tissue sections from 160 ovarian cancer patients whose clinical outcomes had been tracked after first-line treatment. Results The median recurrence-free survival in patients with a positive and negative expression of BubR1 was 27 and 83 months, respectively (P<0.001). A positive BubR1 expression was also associated with advanced stage, serous histology and high grade. In contrast, Aurora A immunostaining did not correlate with any of the clinical parameters analysed. Conclusion BubR1, but not Aurora A, is a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers."xsd:string
http://purl.uniprot.org/citations/19603021	http://purl.org/dc/terms/identifier	"doi:10.1038/sj.bjc.6605161"xsd:string
http://purl.uniprot.org/citations/19603021	http://purl.uniprot.org/core/author	"Lee Y.K."xsd:string
http://purl.uniprot.org/citations/19603021	http://purl.uniprot.org/core/author	"Lee H."xsd:string
http://purl.uniprot.org/citations/19603021	http://purl.uniprot.org/core/author	"Choi E."xsd:string
http://purl.uniprot.org/citations/19603021	http://purl.uniprot.org/core/author	"Kim M.A."xsd:string
http://purl.uniprot.org/citations/19603021	http://purl.uniprot.org/core/author	"Park N.H."xsd:string
http://purl.uniprot.org/citations/19603021	http://purl.uniprot.org/core/author	"Park P.G."xsd:string
http://purl.uniprot.org/citations/19603021	http://purl.uniprot.org/core/date	"2009"xsd:gYear
http://purl.uniprot.org/citations/19603021	http://purl.uniprot.org/core/name	"Br J Cancer"xsd:string
http://purl.uniprot.org/citations/19603021	http://purl.uniprot.org/core/pages	"504-510"xsd:string
http://purl.uniprot.org/citations/19603021	http://purl.uniprot.org/core/title	"BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers."xsd:string
http://purl.uniprot.org/citations/19603021	http://purl.uniprot.org/core/volume	"101"xsd:string
http://purl.uniprot.org/citations/19603021	http://www.w3.org/2004/02/skos/core#exactMatch	http://purl.uniprot.org/pubmed/19603021
http://purl.uniprot.org/citations/19603021	http://xmlns.com/foaf/0.1/primaryTopicOf	https://pubmed.ncbi.nlm.nih.gov/19603021
http://purl.uniprot.org/uniprot/#_D6PW95-mappedCitation-19603021	http://www.w3.org/1999/02/22-rdf-syntax-ns#object	http://purl.uniprot.org/citations/19603021
http://purl.uniprot.org/uniprot/#_O60566-mappedCitation-19603021	http://www.w3.org/1999/02/22-rdf-syntax-ns#object	http://purl.uniprot.org/citations/19603021
http://purl.uniprot.org/uniprot/O60566	http://purl.uniprot.org/core/mappedCitation	http://purl.uniprot.org/citations/19603021
http://purl.uniprot.org/uniprot/D6PW95	http://purl.uniprot.org/core/mappedCitation	http://purl.uniprot.org/citations/19603021